Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kesko Oyj - Managers' Transactions (Rauhala)

Kesko Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Jorma Rauhala Position: Other senior manager  Issuer: Kesko Oyj LEI: 743700OX6HSVMCAHPB95 Notification type: INITIAL NOTIFICATION Reference number: 42878/4/4 ____________________________________________ Transaction date: 2023-11-06 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009000202 Nature of transaction: ACQUISITION Transaction details (1): Volume: 202 Unit price: 16.565 EUR (2):

BioStock: Enzymatica focuses on strengthening the distributor level

Following a promising start to the year with strong initial sales, Enzymatica experienced a decline in sales during the third quarter, primarily attributed to reduced order intake from their key partner, STADA. The company has engaged in discussions with STADA to explore the best way forward, and initiated talks with new possible partners for several of their primary markets. During the third quarter, Enzymatica also presented positive study results that are expected to play a crucial role in market launches, according to an interview with CEO Claus Egstrand.Read the full article at

White Pearl Technology Group to deliver IT resources for over SEK 20 million to South African municipality

The City of Tshwane Metropolitan Municipality, situated in the densely populated area of Gauteng in South Africa, serves over three million residents and has appointed WPTG as a strategic partner through a tender process. White Pearl Technology Group AB (WPTG) will provide IT services and skills to optimize its mission-critical systems for a period of three years, at a value of more than SEK 20 million.WPTG's subsidiary, InTheNet Technologies (ITNT), based in South Africa, is the key strategic partner that will support Tshwane on site, with its critical IT systems across key areas such as

Synsam invites you to a video presentation of the third quarter 2023 interim report and a live Q&A session

Synsam AB (publ) will release its third quarter 2023 interim report on Friday, November 17th at 07:30. At the same time, the company will publish a video presentation of the quarterly results with CEO Håkan Lundstedt and CFO Per Hedblom. At 09:00 the same day, you will have the opportunity to participate in a live Q&A session, in Swedish, with Håkan Lundstedt and Per Hedblom. The quarterly presentation is video materials created to complement the interim report and provide further insight and better understanding of the company's operations for the stock market. The presentation material

Correction: Interim Report Q3 2023: Building momentum for a promising 2024

Company Announcement no. 28/20238 November 2023   Wirtek’s Board of Directors has today approved the interim report for Q3 2023. Below a summary - the detailed report is attached to this announcement. CEO Michael Aaen comments: “In Q3 2023, we have seen an inflow of new orders from both existing and new clients, especially in our Energy business unit, having full revenue effect from 2024. This makes us confident about an increasing activity level in 2024. That said, the market condition in Q3 2023 has been challenging for some of our clients, and an inflation-driven increase

Announcement of Mandatum plc’s results and Annual General Meeting in 2024

Mandatum plc, Stock exchange release, 8 November 2023 at 10:15 EET  Mandatum plc will publish a Financial Statement Release for 2023 on 13 February 2024. Mandatum will report its results on following days during 2024: - 8 May 2024: Interim Statement for the period January–March 2024 - 13 August 2024: Half-Year Financial Report for the period January–June 2024 - 12 November 2024: Interim Statement for the period January–September 2024 The Financial Statements and the Board of Directors’ Report, as well as the Corporate Governance Statement, the Remuneration Report for

Interim Report Q3 2023: Building momentum for a promising 2024

Company Announcement no. 28/20238 November 2023   Wirtek’s Board of Directors has today approved the interim report for Q3 2023. Below a summary - the detailed report is attached to this announcement. CEO Michael Aaen comments: “In Q3 2023, we have seen an inflow of new orders from both existing and new clients, especially in our Energy business unit, having full revenue effect from 2024. This makes us confident about an increasing activity level in 2024. That said, the market condition in Q3 2023 has been challenging for some of our clients, and an inflation-driven increase

A thyroxine derivative enhances brain drug delivery

A new study from the University of Eastern Finland shows that the delivery of drugs into the brain, and especially into glial cells, can be enhanced with prodrugs that temporarily incorporate thyroxine or a thyroxine-like molecule. The transporter protein OATP1C1, which is found in the brain, can be utilised in the delivery of such prodrugs. The results were published in Journal of Medicinal Chemistry. For the first time ever, researchers used the organic anion-transporting polypeptide 1C1 (OATP1C1) to enhance drug delivery into the brain. In the study, prodrugs were used to transport

Cereno Scientific’s drug candidate CS585 highlighted by top-tier medical journal Blood as a promising novel anti-thrombotic strategy without risk of bleeding

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the recently published paper on CS585 in the top peer-reviewed medical journal Blood was selected to feature in the journal’s Blood Podcast as well as awarded a commentary titled “Targeting prostacyclin: all gain with no pain?” concluding that the discoveries reported by Stanger and colleagues mark an important milestone to improve anti-thrombotic strategies.The article published in Blood shows that CS585, a prostacyclin receptor agonist,

Momentum in Indian biogas development drives multiple sales of BPC’s products

BPC Instruments AB (“BPC” or the “Company”) is experiencing an increased sales momentum in India and is pleased to announce that the Company has received purchase orders from three Indian biogas companies for the delivery of several of the Company’s flagship analytical instruments with a total order value of over 94 000 Euro. The revenue from the orders is expected to be included in the fourth quarter of this year.BPC has received orders consisting of two AMPTS[®], one BioReactor Simulator, one Gas Endeavour[®] Core, one BPC[®] Go, one bioreactor, and other accessories via Arka BRENStech –

Scania and sennder establish JUNA, a joint venture to drive large-scale electric truck adoption and accelerate decarbonisation of European road logistics

• By combining sennder’s advanced technology with Scania’s premium electric truck offering, JUNA introduces a pioneering pay-per-use model that provides transport companies with access to electric truck solutions and guaranteed capacity.• The flexible service model makes it easier for carriers to switch to electric trucks, eliminating upfront costs and potential residual value concerns. And, by offering access to guaranteed loads on sennder’s digital platform, JUNA ensures commercial predictability for its customers.• JUNA, that just started operating together with a first pioneering

Neste’s ownership in Neste Demeter increases

Neste Corporation, Press Release, 8 November 2023 at 10 a.m. (EET) Neste, a producer of renewable fuels from waste and residues, has acquired 29% of the shares of Neste Demeter B.V., increasing Neste’s ownership to 80% of the company. Neste has also agreed to acquire the remaining shares of Neste Demeter B.V. over the next few years as agreed with the minority shareholders. Neste announced 3 September 2018 the acquisition of 51% of the shares of IH Demeter B.V. ,

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 191 - 8 NOVEMBER 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 186/23 and 187/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Zwipe AS - key information relating to the proposed rights issue of NOK 35 million

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ZWIPE AS. SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW IN THIS DOCUMENT. Reference is made to the stock exchange announcement published by Zwipe AS ("Zwipe" or the "Company") on 8 November 2023, in which the Company

Mandatum Group’s result for January-September 2023

Mandatum plc, Stock exchange release/Interim Report, 8 November 2023 at 9:45 EET  Mandatum Group’s result for January-September 2023 · The Group’s profit before taxes for the period increased to EUR 164.1 million (13.11). Growth was particularly seen in the net finance result, which was driven not only by a good investment return but also by a strong increase in the discount rate for insurance contract liabilities in the third quarter. · The Group’s fee result was EUR 39.2 million (37.1). · Net flow for the period amounted to EUR 543.9 million (300.0) indicating an increase of

Inhalation Sciences secures new order worth 54,700 Euro

(Stockholm, Sweden, 8 November,2023) Inhalation Sciences AB has signed a new order valued at 54,700 Euro with a customer in Europe developing a generic inhaled drug-device combination therapy. The order is the result of a collaboration with a trusted partner specializing in regulatory tests comparing test and reference inhalers.Inhalation Sciences has received an order valued at 54,700 Euro with a new customer in Europe developing a generic inhaled drug-device combination therapy. The project will carry out required regulatory testing through a trusted service partner, sourced by ISAB, that

Scantox appoints Morten Fjordholt as Sr. Business Development Director

November 8th – Scantox Group, a leading provider of nonclinical services in Europe, has named Morten Fjordholt as Sr. Business Development Director with the overall responsibility of growing sales within toxicology and lab services and fostering positive relationships with current and prospective clients. Morten Fjordholt is an experienced Molecular Biologist and pharmaceutical Toxicologist with over two decades of experience in the life science and drug development industry. Morten has made significant contributions to our industry. Over the past eight years, he played a crucial role in

Peptonic's self-test for bacterial vaginosis to be sold in over 220 Apoteket stores

Peptonic Medical AB (publ) ("Peptonic") announced today that the company's patented product for self-testing of bacterial vaginosis, VagiVital VS, is being offered for sale in over 220 Apoteket stores in Sweden.”It is very gratifying that Apoteket is starting to sell VagiVital VS in its physical stores. VagiVital VS will broaden Apoteket's offer to many women because they already sell Pharmiva's treatment Vernivia against bacterial vaginosis. The agreement is further proof that our unique holistic concept of Diagnosing, Treating and Preventing attracts both end customers and distribution

2020 Bulkers Ltd. (2020) – Commercial update and key information relating to the cash distribution for October 2023

Oslo, Norway, November 8, 2023 Commercial update: In October 2023, the Company achieved average time charter equivalent earnings of approximately US$36,300 per day, gross, for its vessels trading on index-linked time charter, including average daily scrubber benefits of approximately US$1,500 per day. The Baltic 5TC Capesize Index averaged US$25,557 during October 2023. Cash Distribution: The Board has approved a cash distribution of US$0.2 per share for October 2023. The distribution will be made from the Company’s Contributed Surplus account which consists of previously

Gaming Innovation Group reports Q3 2023

Gaming Innovation Group Inc. (GiG) reports Q3 2023 revenues* of €31.8 million and an adjusted EBITDA of €23.4 million.  “I am delighted to share with you the strong Q3-2023 results for Gaming Innovation Group, as we continue our journey towards becoming world leaders in the iGaming industry, focusing on our two core business areas, Media and Platform & Sportsbook. The third quarter of 2023 has proven to be another period of growth and achievement”, says Petter Nylander, Chairman of GiG.  Financial Highlights · Gaming Innovation Group achieved all-time high revenues* in Q3 2023

Hufvudstaden retains top ranking in international Global Real Estate Sustainability Benchmark

Hufvudstaden has once again topped the “Offices and Retail” Europe category in the Global Real Estate Sustainability Benchmark (GRESB) ranking, with a total of 93 points and five out of a possible five stars for the third consecutive year.GRESB is an annual evaluation of property companies’ sustainability performance on areas such as the environment, social sustainability, governance and follow-up. In this year’s ranking, Hufvudstaden achieved 93 points out of 100. The average score was 76 in the Offices and Retail category. “We’re so proud to have maintained our top score in the GRESB

Interim Report for the period July – September 2023

LEQEMBI launched in the USEvents during the third quarter 2023 · In July, the FDA approved LEQEMBI® for the treatment of Alzheimer’s disease in the US and the Centers for Medicare and Medicaid Services, CMS, announced that LEQEMBI will be reimbursed according to the FDA approved label · In September, LEQEMBI was approved for the treatment of Alzheimer's disease in Japan, which entitled BioArctic to a milestone payment of EUR 17 M, equivalent to SEK 201.0 M · The board has decided to initiate a Phase 2a study of exidavnebab (BAN0805) in Parkinson's disease. The study is expected

2020 Bulkers Ltd. (2020) - Results for the third quarter of 2023

Oslo, Norway, November 8, 2023 2020 Bulkers Ltd. (“2020 Bulkers” or the “Company”), today announced its unaudited financial and operating results for the three and nine months ended September 30, 2023. Key events during the third quarter of 2023 · The Company reported net profit of US$5.2 million and EBITDA of US$11.1 million for the third quarter of 2023. · Achieved average time charter equivalent earnings of approximately US$21,000 per day, gross. · The Company declared total cash distributions of US$0.12 per share for the months of July, August and September 2023.

CONCENTRIC INTERIM REPORT JANUARY – SEPTEMBER 2023

THIRD QUARTER 2023 · Net sales: MSEK 1,035 (1,068) – reported sales were down -3% year-on-year. After adjusting for the impact of currency +4%, sales on a like for like basis, in constant currency year-on-year were down -7%. · Operating income: MSEK 134 (175), generating an operating margin of 13.0% (16.3). After adjusting for the cost associated with the closure of Itasca of MSEK 12, the operating margin before items affecting comparability was 14.1% (15.5). · Net income for the period: MSEK 89 (126); basic EPS of SEK 2.35 (3.32). · Cash flow from operating activities: Strong

There are no items matching the current filter
There are no more items matching the current filter
Back to top